New York, January 8, 2026, 14:40 EST — Regular session
- TMO down 0.25% at $615.61; traded between $611.98 and $623.20
- TD Cowen lifted its price target to $696 and kept a Buy rating
- Investors eye the Jan. 13 JPM talk and Jan. 29 earnings for a 2026 outlook check
Thermo Fisher Scientific Inc (TMO) shares slipped 0.25% to $615.61 on Thursday afternoon after touching $623.20 earlier in the session. About 1.5 million shares had changed hands.
The pullback comes after a sprint that pushed the stock to a record close of $620.72 on Tuesday, when it notched a fresh 52-week high. Investors are now leaning into the next batch of signals, with little room for muddle.
TD Cowen raised its price target on Thermo Fisher to $696 from $654 and kept a Buy rating, according to a note carried by TheFly. The broker said the recent share rally has lifted expectations for fourth-quarter results, with some companies already signaling a conservative early view for 2026; Cowen’s target implies roughly 13% upside from current levels.
Thermo Fisher has also been pointing investors to its push into so-called real-world evidence — data gathered from doctors and patients outside clinical trials. The company said it enrolled the first patient in a new PPD CorEvitas Obesity Registry, designed to track long-term effectiveness and safety for obesity management therapies, including anti-obesity medicines. “The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice,” said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries at Thermo Fisher. Business Wire
Management will have another shot at shaping expectations next week. The company said Chief Executive Marc Casper will present at the J.P. Morgan 2026 Healthcare Conference on January 13 at 11:15 a.m. ET, with a webcast available on its investor site.
The more direct catalyst is earnings. Thermo Fisher said it will release fourth-quarter and full-year 2025 results before the market opens on January 29 and hold a conference call at 8:30 a.m. ET; investors will listen hard for what that says about lab spending and the 2026 setup.
Life-science tools names traded mixed as the broader market softened. Danaher was up about 0.2% and Agilent fell about 0.4%, while the SPDR S&P 500 ETF was little changed and the Nasdaq-heavy QQQ was down about 0.8%.
But expectations are rising with the price. With the stock hovering around the $620 area, any hint of slower orders or a cautious tone on 2026 could bite harder than it would have a month ago.
Traders will watch whether TMO can hold above the day’s low near $612 and push back through the $623 intraday peak, with Casper’s remarks on January 13 and the January 29 results as the next tests.
